跳到主要内容
Learn Motion
探索课程产品能力价格

下载 Learn Motion

用手机扫描二维码,下载 App。

App Store

扫码从 App Store 下载 Learn Motion打开商店页面

Google Play

扫码从 Google Play 下载 Learn Motion打开商店页面
登录
Learn Motion

How Doctors Judge Whether a Medical Study Can Be Trusted

1The Clinical Question and Why Study Design Follows From It2Randomization, Allocation, and the Logic of Comparison3Blinding, Follow-Up, and Who Actually Got Analyzed4Reading the Result: Effect Size, Uncertainty, and Significance5Applicability: Does This Result Fit My Patient?6Combining Studies and Forming a Verdict
Blinding, Follow-Up, and Who Actually Got Analyzed

Who Is Blinded, and What Each Role Protects Against

1 / 3
Think of blinding as three separate locks on the same door, not one. Participants who know their assignment may change their own behavior — adherence, activity, other care — and that is performance bias. Providers who know may deliver extra monitoring or treatment to one arm, which is also performance bias, but through the care given rather than the participant's choices. Outcome assessors who know may measure or judge differently between arms, and that is detection bias. Notice that detection bias matters most for subjective outcomes like pain scores, where judgment enters the measurement, and barely at all for something like all-cause mortality. So when you appraise a trial, do not ask whether it was blinded. Ask which roles were blinded, and whether the outcomes that matter are the kind that an unblinded assessor could distort.
0:00 / 0:00

Blinding is not a single yes-or-no property of a trial. It is a set of role-specific safeguards, and each role, if unblinded, opens a different route for bias.

Participants who know their assignment can change their behavior — adherence, diet, activity, use of other care — in ways that differ between arms. This is performance bias: the groups no longer receive the same co-interventions, so the comparison of outcomes reflects the behavior change as well as the treatment.

Providers who know the assignment can treat the two arms differently in ways that are not part of the protocol: extra monitoring, additional medications, different encouragement. This is also performance bias, and it operates through the care delivered rather than through the participant's own choices.

Outcome assessors who know the assignment can measure or judge outcomes differently between arms — a slightly more attentive examination, a more generous reading of an ambiguous scan, a different threshold for calling an event. This is detection bias, and it is especially important for subjective outcomes such as pain scores or functional status, where judgment enters the measurement. For an objective outcome such as all-cause mortality, the assessor's knowledge has little room to change the recorded result.

A trial can be double-blind for participants and providers but have unblinded outcome assessors, or vice versa. The appraisal question is therefore not "was the trial blinded?" but "which roles were blinded, and for which outcomes does that matter?"

参考资料

  1. [1]Cochrane Handbook for Systematic Reviews of Interventions, Chapter 8: Assessing risk of bias in a randomized trialtraining.cochrane.org
上一页1 / 3下一页

Learn Motion

生成课程,认真学会。

运营方:Wuhan Daoyin Technology Co., Ltd.

联系我们: [email protected]
隐私政策用户服务协议

© 2026 Learn Motion